Taysha gene therapies to participate in upcoming november investor healthcare conferences

Dallas--(business wire)--taysha gene therapies, inc. (nasdaq: tsha), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing aav-based gene therapies for the treatment of monogenic diseases of the central nervous system (cns) in both rare and large patient populations, today announced its participation in the stifel 2021 virtual healthcare conference, jefferies london healthcare conference, and the 4th annual evercore isi healthconx virtual conference. co
TSHA Ratings Summary
TSHA Quant Ranking